Expression Profiling of Autism Candidate Genes during Human Brain Development Implicates Central Immune Signaling Pathways

Mark N. Ziats1,2,3*, Owen M. Rennert1

1Laboratory of Clinical and Developmental Genomics, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, United States of America, 2Medical Scientist Training Program, Baylor College of Medicine, Houston, Texas, United States of America, 3Department of Physiology, Development and Neuroscience, National Institutes of Health-University of Cambridge Biomedical Scholars Program, Cambridge, United Kingdom

Abstract

The Autism Spectrum Disorders (ASD) represent a clinically heterogeneous set of conditions with strong hereditary components. Despite substantial efforts to uncover the genetic basis of ASD, the genomic etiology appears complex and a clear understanding of the molecular mechanisms underlying Autism remains elusive. We hypothesized that focusing gene interaction networks on ASD-implicated genes that are highly expressed in the developing brain may reveal core mechanisms that are otherwise obscured by the genomic heterogeneity of the disorder. Here we report an in silico study of the gene expression profile from ASD-implicated genes in the unaffected developing human brain. By implementing a biologically relevant approach, we identified a subset of highly expressed ASD-candidate genes from which interactome networks were derived. Strikingly, immune signaling through NFKB, TNF, and JNK was central to ASD networks at multiple levels of our analysis, and cell-type specific expression suggested glia—in addition to neurons—deserve consideration. This work provides integrated genomic evidence that ASD-implicated genes may converge on central cytokine signaling pathways.

Introduction

The Autism Spectrum Disorder is a heterogeneous neurodevelopmental syndrome defined by impairments in communication, social interaction, and restricted or stereotyped patterns of behavior. ASD is the most heritable of the common neuropsychiatric conditions with estimates approaching 90% in monozygotic twins, 10% in dizygotic twins, and recurrence risk in siblings 10–100 times the general population [1,2,3,4]. Moreover, approximately 10–20% of ASD cases are associated with recognizable syndromes of known etiology—representing a large number of rare alleles [5]. With recent advances in comparative genomic hybridization (CGH), approximately 40% of patients with a diagnosis of ASD will have a detectable genomic aberration [6]. However, this genetic etiology is complex and likely involves gene-gene, gene-environment, and epigenetic interactions, reflecting the overlying broad clinical presentation of ASD. This is evidenced by the less than 100% penetrance in identical twins, the discordance in heritability between mono- and dizygotic twins, and the considerable variability within pedigrees [7,8]. Furthermore, the clinical phenotype and underlying genetics of the syndromic forms of ASD are extremely varied, and differences in manifestations of the three core symptoms are observed even within a specific diagnostic entity. Moreover, ASD shares considerable clinical and genetic overlap with other neuropsychiatric disorders such as schizophrenia and mental retardation [9], and ASD patients have significantly increased neurologic comorbidities like hypotonia, tics, and epilepsy [10]. In fact, many of the same gene mutations have been found to predispose to more than one of these neurodevelopmental disorders [11,12].

Consequently, the approximately 60% of non-syndromic ASD cases without an identifiable structural variation (here defined as “intrinsic” Autism) represent a broad clinical spectrum with strong genetic underpinnings that have proven exceedingly difficult to define. Much work has attempted to elucidate the molecular genetics underlying intrinsic Autism, with many linkage, functional, and genome-wide association studies (GWAS) having implicated more than 200 loci to date [13,14,15]. Additionally, copy number variation (CNV) and cytogenetic analysis have further identified many chromosomal hot spots in ASD [16,17]. It is apparent from these studies that many different loci, each with a presumably unique yet subtle contribution to neurodevelopment, underlie the phenotype of ASD. These observations have prompted a shift in the paradigm of ASD genetics away from a common disease/common variant model, to one that recognizes the contribution of rare variants [5,9]. Because of this great clinical and genetic heterogeneity, attempts to identify a common molecular pathology for ASD have remained elusive, and as a result, diagnosis and treatment are non-specific and suboptimal.
Although Autism currently lacks any unifying principles at the genetic and molecular levels, both human and animal studies have begun to demonstrate that disruption of synaptogenesis and improper connectivity of local and distant brain networks likely underlie the cellular pathophysiology responsible for the broad ASD phenotype [18,19]. Multiple different brain regions have been implicated in both post-mortem and neuroimaging studies, notably the prefrontal and temporal cortices, and the cerebellum [20]. Histological analysis has revealed increased cell densities, changes in synaptic spine morphology, mini-columnar disorganization, and glial activation [21]. Despite these observations, the mechanism(s) responsible for this “disconnection” phenotype remains obscure, as a complex interplay between diverse cell types and functions modulate the developing network architecture in both a temporal and spatially regulated manner [22,23,24]. A main question in ASD research has become, then, how to reconcile the genetic and phenotypic heterogeneity with the apparent synaptic network abnormalities underlying the broad ASD phenotype.

A proposed unifying explanation for this dichotomy posits that differences in gene expression in the developing brain could explain how many genes, each with a different contribution to proper formation of brain circuitry, could result in a single disorder with neural network dysfunction at its core [25,26]. This model is underscored by the prototypical Autism Spectrum Disorder, Rett Syndrome, in which mutations in the MeCP2 gene result in global dysregulation of the transcriptome [27]. Moreover, it has been shown that mutations in MeCP2—a transcriptional repressor—result in aberrant expression at many ASD-implicated loci [28]. To investigate this model, however, requires gene expression profiling of ASD-candidate genes in developing human brain tissue. To date, a number of studies have investigated gene expression in ASD (for review see [29]), with three examining ASD brain tissue on a genome-wide scale [30,31,32]. However, no expression profiling of genes implicated in ASD, Epilepsy, Autism that are described in the database AutDB (Table S1), was not expressed as expected. Neurofilament (Nefl), an astrocyte-specific intermediate filament (Nefl), a neuron-specific marker, showed high expression in most brain regions after 24 weeks gestation (wg). Notably, expression of Nefl was significantly lower in the cerebellum, which is consistent with our observation at the protein level (see below). Expression of Glial Fibrillary Acid Protein (GFAP), an astrocyte-specific intermediate filament, also showed high expression in all brain regions beginning at the fourth postnatal month, although markedly later in development than Nefl. Interestingly, Vimentin, a marker of mesenchyme-derived cells, exhibits a differential expression pattern with very high expression in the early developing brain (24 wg–4 mo). This may be a reflection of invading microglia, which are of mesenchymal origin and known to enter the developing brain during early embryogenesis [40], and/or it may relate to the laying down of the vasculature and extracellular matrix early in development.

Expression of Brain-specific markers

We analyzed genes of brain-specific markers (adhésion/elastic/ filament proteins) with intermediate expression to further validate our method and gain insight into cell-type specific expression across brain regions and during different developmental time points. As seen in Figure S3, Keratin and Desmin—markers of epithelia and muscle, respectively—were not expressed as expected. Neurofilament (Nefl), a neuron-specific maker, showed high expression in most brain regions after 24 weeks gestation (wg). Notably, expression of Nefl was significantly lower in the cerebellum, which is consistent with our observation at the protein level (see below). Expression of Glial Fibrillary Acid Protein (GFAP), an astrocyte-specific intermediate filament, also showed high expression in all brain regions beginning at the fourth postnatal month, although markedly later in development than Nefl. Interestingly, Vimentin, a marker of mesenchyme-derived cells, exhibits a differential expression pattern with very high expression in the early developing brain (24 wg–4 mo). This may be a reflection of invading microglia, which are of mesenchymal origin and known to enter the developing brain during early embryogenesis [40], and/or it may relate to the laying down of the vasculature and extracellular matrix early in development.

Expression Profile of genes implicated in ASD, Epilepsy, and Schizophrenia

We parsed the NIMH database for all genes implicated in Autism that are described in the database AutDB (Table S1 and Methods). To strengthen our approach and investigate the
overlapping genetic and clinical aspects of Schizophrenia and Epilepsy with ASD, we also investigated all genes implicated in these disorders, which are cataloged in the databases SZGene and CarpeDB, respectively (Table S1). Non-redundant, protein-coding loci that were present in the NIMH atlas were included in this study, as summarized in Figure 1. Only 11 genes are shared by all three disorders. Gene ontology (GO) enrichment analysis of these 11 overlapping genes as opposed to all genes implicated in all three disease databases yielded many significant pathways mainly involved in the response to external stimuli and GABA metabolism (Table 1).

We constructed expression heatmaps for all genes by brain region and time-point by assigning each RPKM expression value to one of five quintiles, and then grouping genes into five expression tiers (see Methods; Tables S2, S3, S4). Strikingly, for each of the three disease sets more than 55% of genes were never expressed above 20 RPKM, with the majority of these less than 5 RPKM (Table 2). For ASD candidate genes, greater than 70% were not expressed highly in each brain region. In each region, a large percentage of ASD-implicated genes had no detectable transcription (<1 RPKM). For instance, in the hippocampus 46 out of 219 (21%) ASD-implicated genes had no detectable transcripts. Similar proportions were not detected in the cerebellum (52/219 or 24%) or dorsolateral prefrontal cortex (40/219 or 18%). While it is possible that these loci still have functional roles in ASD genomics via cis-regulation or other mechanisms, we reasoned that their inclusion in protein-interaction networks might obscure more prominent molecular mechanisms underlying ASD.

It is of note that the cerebellum and frontal cortex contained the greatest number of highly expressed “Autism genes” and the temporal cortex had the greatest number of “Epilepsy genes,” whereas Schizophrenia gene expression distributed more evenly throughout the brain. While much work in Autism has focused on the hippocampus as a potential epicenter of pathology, we found the developing hippocampus had the fewest ASD candidate genes expressed at high levels, and none were specific for the hippocampus. Conversely, the cerebellum contained a unique set of six Autism candidate genes that were not highly expressed in any other brain region. These included the canonical neurodevelopmental genes Nlgn3 and Robo, two cell adhesion molecules, and 7-dehydrocholesterol reductase. This is intriguing since multiple imaging studies have implicated the cerebellum in the pathogenesis of Autism [41]. The NIMH Atlas parcels the frontal cortex into four subregions, yet the expression profile of ASD genes between them was similar. Only one gene (Gabrb3) was specific to the frontal cortex, and it was only present at high levels in the ventrolateral prefrontal cortex. Interestingly, this gene lies in the 15q11–13 imprinted region implicated in Prader-Willi and Angelman Syndromes, and is one of the most reproducible loci identified in ASD genome-wide association studies [42].

For the remainder of our analysis, we focused on genes in the top three expression tiers (at least one time-point >60 RPKM) as genes that are significantly highly expressed as compared to all ASD-implicated genes (based on our “housekeeping gene” results). This yielded 32 genes for Autism, 42 for Epilepsy and 212 for Schizophrenia (Fig. 2). Autism shared eight highly expressed genes with Schizophrenia, and only two with Epilepsy (Dcx and Cnr1). GO Figure 1. Summary of all genes analyzed from AutDB, CarpeDB and SZGene. Number of genes and genes shared between disorders indicated. doi:10.1371/journal.pone.0024691.g001
enrichment of these nine shared genes did not identify any significant pathways. There was only one gene—Cannabinoid Receptor 1 (*Cnr1*)—implicated in all three disorders that is highly expressed in the developing brain. *Cnr1* expression is high mainly during gestation, and is most pronounced in the cerebellum and amygdala (Fig. S4).

Nine Autism genes were highly expressed in all brain regions examined. These nine genes (*Fabp7, Gnas, Gpx1, Hnrnph2, Hras, Pdzd4, Rpl10, Sez6l2, and Tspan7*) had considerably higher expression than all other ASD genes (over 500 RPKM in many instances, Fig. S5). Their temporal expression profiles were mostly constant across developmental stages, except for *Fabp7*, which exhibited drastic differential expression. *Fabp7* was expressed much higher than the other eight genes during almost all time-points, but was highest during the two gestational time points. Interestingly, *Fabp7* (Fatty acid binding protein 7) is known to interact with *Notch* in radial glia during development [43], and we subsequently found it to only be expressed in glia (see below). The temporal expression of the other 32 highly expressed genes varied considerably, but was biased toward high expression in the early time points analyzed (Table S5).

Gene ontology enrichment of the 32 highly expressed Autism genes revealed four new GO categories representing two significant processes—immune system regulation and apoptosis (Table 5). GO enrichment of the highly expressed Schizophrenia genes yielded a much different set of processes, mostly implicating cellular morphogenesis, but none involving the immune response (Table 4). The epilepsy dataset did not enrich for any significant functions when considering those genes that were highly expressed. This suggests that ASD-implicated genes with no or low expression in the developing brain may obscure functional pathway analysis, which otherwise implicates cytokine signaling.

### Network Analysis

Next, we set out to determine if the genes we identified as being highly expressed in the developing brain implicate different functional networks as compared to all genes associated with these diseases. We utilized integrated gene-network analysis using the curated Ingenuity Pathway Analysis (IPA) database. Initially we searched for canonical pathways for each disorder, comparing the highly expressed gene sets to all disease-associated genes (Tables 5, 6, 7). This analysis implicated many new canonical pathways from the set of highly expressed genes not seen in the full dataset analysis. For Autism, this included corticotrophin releasing hormone signaling, g-protein and phospholipase C signaling, and neutrophil cytokine signaling. The new pathways implicated in Schizophrenia included synaptic long-term potentiation and axon guidance signaling, and in Epilepsy semaphorin signaling and the spliceosome cycle. Interestingly, there are no canonical pathways shared between the three disorders when the entire set of implicated genes is considered, but analysis of the highly expressed sets implicates Reelin Signaling in Neurons as common to all three disorders. Further investigation of this pathway (Fig. S6) shows almost all molecules are implicated in at least one of these three neurodevelopmental disorders.

Unbiased gene-network analysis was then constructed in IPA, to identify connectivity networks derived from the enriched gene set.
compared to those derived from all Autism-associated genes. Overlaying derived networks based on connectivity revealed that the two networks constructed from the highly expressed ASD genes are central to all networks obtained from all ASD-associated genes (Figure 3). In the first central network (Figure 4), \textit{NfkB}, \textit{Jnk}, and \textit{Mapk} are hubs. Network 2 from the highly enriched set also contains \textit{NfkB} as a hub, in addition to \textit{Tnf}, \textit{TgfB1} and \textit{Myc} (Figure 5). Taken together, these enriched networks, which are the most inter-connected of all ASD-derived networks, have at their core fundamental cytokine signaling molecules not previously implicated as ASD susceptibility loci. These may serve as potential final common pathways through which the heterogeneous ASD-implicated genes ultimately converge. Moreover, this represents a third, independent level of analysis whereby the highly expressed ASD genes implicate immune signaling pathways that are not apparent when the full set of ASD-associated genes is considered.

Similar analysis comparing ASD-associated gene networks specific to brain regions did not result in a significant clustering by region, nor were there central network nodes (Fig. S7). Considering only genes expressed highly during gestational time points, we did not observe any new pathways or networks not already implicated using all time points.

Gene-network analysis of the Epilepsy and Schizophrenia gene sets did not result in centrality of the highly expressed networks as we observed in ASD (Figures S8 and S9), perhaps reflecting the less heterogeneous nature of these disorders.

Correlating Gene Transcription with Cell-type Specific Protein Expression

Next, we were interested in correlating our ASD gene transcriptome results with protein expression levels in a cell-type specific manner. To do so, we mined the Human Protein Atlas database for the 32 highly expressed Autism genes (see Methods, Table 2).

**Table 3. GO enrichment analysis of highly expressed Autism genes.**

| GO Term     | Description                               | P-value |
|-------------|-------------------------------------------|---------|
| GO:0002682  | regulation of immune system process       | 0.0001  |
| GO:0006915  | apoptosis                                 | 0.0009  |
| GO:0012501  | programmed cell death                     | 0.0009  |
| GO:0031347  | regulation of defense response             | 0.0009  |

**Table 4. GO enrichment analysis of highly expressed Schizophrenia genes.**

| GO Term     | Description                               | P-value |
|-------------|-------------------------------------------|---------|
| GO:0048812  | neuron projection morphogenesis           | 0.00001 |
| GO:0032990  | cell part morphogenesis                    | 0.00002 |
| GO:0048858  | cell projection morphogenesis              | 0.00002 |
| GO:0032989  | cellular component morphogenesis           | 0.00007 |
| GO:0007409  | axonogenesis                               | 0.00007 |
| GO:0090066  | regulation of anatomical structure size    | 0.00008 |
| GO:0051129  | negative regulation of cellular component organization | 0.00063 |
| GO:0032535  | regulation of cellular component size      | 0.00065 |
| GO:0010721  | negative regulation of cell development    | 0.00083 |
| GO:0007417  | central nervous system development         | 0.00083 |
| GO:0030030  | cell projection organization                | 0.00084 |
| GO:0031344  | regulation of cell projection organization  | 0.00096 |
We were surprised to find that many highly expressed ASD genes are mainly detected in glia not neurons, and/or in specific layers of the cerebellum. A similar proportion of genes exhibit neuron-specific protein expression. We also observed that Gnas, a complex locus known to be imprinted and express antisense and non-coding transcripts [44], does not appear to make detectable protein in the CNS, yet is one of the 9 most highly expressed ASD transcripts in the NIMH atlas. Fabp7, which we noted was the most highly expressed ASD-associated gene, is only detected in glia. Moreover, Cnr1—the one highly expressed gene shared by all three disorders—is most highly expressed in glial cells and the molecular layer of the cerebellum. These results suggest future investigation of cell-type specific expression in ASD will be an important undertaking, and consideration of non-coding RNAs in ASD pathogenesis is warranted as well.

Analysis of ASD Transcriptome Data

Lastly, we were interested in considering our findings in the context of the major three published transcriptomics studies on ASD brain tissue [30,31,32]. Two of these have implicated immune alterations in ASD brain as compared to controls. We examined the results of all three studies to determine how many of the dysregulated genes reported were ASD implicated genes present in AutDB. Surprisingly, in each study only ~5% of genes that are significantly different between ASD and control brains were previously implicated in ASD (Table 9). This underscores the importance of our findings on ASD-implicated genes, as both our approach and whole-transcriptomics studies implicate immune signaling pathways, even though most ASD-implicated genes we profiled are not dysregulated in ASD brain tissue.

Discussion

In an attempt to integrate the genomic heterogeneity underlying the complex etiologies of common neurodevelopmental disorders, we report here the analysis of expression from all implicated genes in Autism, Schizophrenia, and Epilepsy using next-generation transcriptome sequencing in the developing human brain. Sakai et al recently constructed a protein interactome network using a

Table 5. Canonical Pathways implicated in ASD when considering all genes versus highly expressed genes.

| Canonical Pathways Derived from All AutDB Genes | P-Value | Canonical Pathways Derived from 32 Highly Expressed ASD Genes | P-Value |
|-----------------------------------------------|--------|------------------------------------------------------------|--------|
| Serotonin Receptor Signaling                   | 4.4E-08| Corticotropin Releasing Hormone Signaling                   | 4.5E-05|
| Reelin Signaling in Neurons**                 | 5.4E-06| G-Protein Coupled Receptor Signaling**                     | 2.5E-04|
| HER-2 Signaling in Breast Cancer              | 5.0E-05| Role of NFAT in Cardiac Hypertrophy                        | 3.1E-04|
| cAMP-mediated Signaling**                     | 6.9E-05| Reelin Signaling in Neurons**                               | 3.7E-04|
| G-Protein Coupled Receptor Signaling**       | 7.6E-05| Factors Promoting Cardiogenesis in Vertebrates              | 5.0E-04|
| Virus Entry via Endocytic Pathways**         | 1.7E-04| α-Adrenergic Signaling                                      | 5.1E-04|
| Macropinocytosis Signaling                    | 1.8E-04| cAMP-mediated Signaling**                                  | 5.1E-04|
| Axonal Guidance Signaling                     | 2.2E-04| Virus Entry via Endocytic Pathways**                       | 5.5E-04|
| PTEN Signaling                                | 3.8E-04| G Beta Gamma Signaling                                      | 5.9E-04|
| GABA Receptor Signaling                       | 4.3E-04| Phospholipase C Signaling                                   | 7.2E-04|
| Glioblastoma Multiforme Signaling            | 5.9E-04| Cholecystokinin/Gastrin-mediated Signaling                  | 7.8E-04|
| PI3K/AKT Signaling                            | 9.1E-04| IMLP Signaling in Neutrophils                               | 9.5E-04|

**indicates the pathway was implicated in both sets. #indicates the pathway was common to all three disorders.

doi:10.1371/journal.pone.0024691.t005

Table 6. Canonical Pathways implicated in Schizophrenia when considering all genes versus highly expressed genes.

| Canonical Pathways Derived from All Schizophrenia Genes | P-Value | Canonical Pathways Derived from 212 Highly Expressed Schizophrenia Genes | P-Value |
|--------------------------------------------------------|--------|--------------------------------------------------------------------------|--------|
| Glutamate Receptor Signaling**                         | 1.0E-32| Glutamate Receptor Signaling**                                            | 1.3E-12|
| Amyotrophic Lateral Sclerosis Signaling**              | 4.0E-23| Reelin Signaling in Neurons**                                            | 4.4E-09|
| Neuropathic Pain Signaling In Dorsal Horn Neurons     | 7.9E-22| cAMP-mediated Signaling**                                                | 1.5E-08|
| CREB Signaling in Neurons**                            | 1.0E-21| 14-3-3-mediated Signaling                                                | 4.3E-08|
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritis | 1.3E-20| Axonal Guidance Signaling                                                | 6.6E-08|
| Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis | 1.3E-19| p7056K Signaling                                                        | 8.7E-08|
| G-Protein Coupled Receptor Signaling                  | 4.0E-18| CREB Signaling in Neurons**                                              | 9.1E-08|
| Human Embryonic Stem Cell Pluripotency                | 1.3E-17| Synaptic Long Term Potentiation                                          | 1.9E-07|
| Serotonin Receptor Signaling                          | 5.0E-17| Myc Mediated Apoptosis Signaling                                         | 1.1E-06|
| Glucocorticoid Receptor Signaling                     | 7.9E-17| Amyotrophic Lateral Sclerosis Signaling**                                | 1.1E-06|

**indicates the pathway was implicated in both sets. #indicates the pathway was common to all three disorders.

doi:10.1371/journal.pone.0024691.t006
To do so, we first described gene ontology, canonical pathways, and interactome networks for all genes implicated in ASD that are cataloged in the database AutDB. Then, based on the argument that differential expression of ASD-implicated genes may underlie molecular pathways underlying ASD by investigating as large of a set of ASD candidate genes.

Table 7. Canonical Pathways implicated in Epilepsy when considering all genes versus highly expressed genes.

| Canonical Pathways Derived from All Epilepsy Genes | P-Value | Canonical Pathways Derived from 42 Highly Expressed Epilepsy Genes | P-Value |
|--------------------------------------------------|---------|------------------------------------------------------------------|---------|
| GABA Receptor Signaling**                        | 4.7E-09 | Reelin Signaling in Neurons**#                                   | 1.3E-06 |
| Neuropathic Pain Signaling In Dorsal Horn Neurons | 2.1E-06 | GABA Receptor Signaling**                                        | 2.8E-04 |
| Reelin Signaling in Neurons**                    | 2.6E-05 | Semaphorin Signaling in Neurons                                   | 7.1E-03 |
| β-alanine Metabolism                              | 2.2E-04 | Spliceosomal Cycle                                                | 7.2E-03 |
| Glutamate Receptor Signaling**                   | 7.4E-04 | Glutamate Receptor Signaling**                                   | 1.1E-02 |
| Calcium Signaling                                | 8.5E-04 |                                                                  |         |
| Cellular Effects of Sildenafil (Viagra)           | 1.1E-03 |                                                                  |         |
| Butanoate Metabolism                             | 2.7E-03 |                                                                  |         |
| Hepatic Cholestasis                              | 5.5E-03 |                                                                  |         |
| Glutamate Metabolism                             | 6.0E-03 |                                                                  |         |

**indicates the pathway was implicated in both sets. #indicates the pathway was common to all three disorders.

doi:10.1371/journal.pone.0024691.t007

Figure 3. Overlapping gene-networks in ASD. Networks 1 and 2 (yellow border) were derived from the highly expressed ASD gene set. All other networks were derived from the set of all ASD-implicated genes. Orphaned networks (no edges) were excluded. Edge values represent number of interactions between networks.
doi:10.1371/journal.pone.0024691.g003
the clinical and genetic heterogeneity, we developed a biologically relevant methodology to extract a subset of highly expressed ASD-implicated genes from the NIMH Transcriptional Atlas of Human Brain Development. We found that interactome analysis placed the two networks derived from highly expressed ASD candidate genes at the center of all ASD gene networks. Closer inspection of these networks revealed NFκB, Jnk, MapK, TNF, TGF-B, and Myc as central hubs. These central networks were supported by evidence at two other levels of our analysis (Gene ontology and canonical pathways). Taken together, our findings integrate a large set of genes implicated in ASD and suggest that they may converge onto classical cytokine signaling pathways. While other transcriptomics studies on ASD tissue have implicated immune system signaling in ASD pathogenesis, our findings suggest that the ASD-implicated genes themselves may also be related to these functions.

Interestingly, there is also mounting evidence at the cellular and tissue levels that more in depth investigation of an immune component is warranted in ASD [46]. For instance, multiple studies have demonstrated altered cytokine profiles in ASD patients [47,48], and altered TGF-B concentration in serum and CSF correlates with disease severity [49]. Others have described various autoimmune phenomena including autoantibodies to neural antigens and maternal-fetal cross-reactive neural antibodies [50]. There is also indication of altered innate cellular immunity in ASD, such as differences in gene expression and altered response to immunostimulatory ligands in both natural killer and monocytic cells from ASD patients [51,52]. Post-mortem brain tissue from ASD patients shows increased microglial density in grey matter, an activated morphology, and secretion of a cytokine profile consistent with a pro-inflammatory state, most prominent in the cerebellum [53,54]. Moreover, microglia from MeCP2- null mice—a model of the Autism Spectrum Disorder Rett Syndrome—produce a conditioned media that damages synaptic connectivity via a glutamate-excitotoxicity mechanism [55].
all of this work provides post-hoc evidence for altered immune response in ASD, our results suggest a direct link between implicated genes in ASD and molecular pathways involved in immune signaling.

This considerable attention to the immune response in previous ASD research has resulted in two prevailing theories: one suggests exogenous factor(s) stimulate neuro-inflammation during development, while the other postulates autoimmune activation causes ASD pathology [56,57]. However, it is equally possible—as our results support—that the mutations described in ASD result in aberrant signaling regulation of immune cells during neurodevelopment. This could result in cell-autonomous activation and/or improper response to otherwise nominal stimuli, such as occurs in the autoimmune syndromes [58]. Alternatively, as glia are increasingly implicated in normal formation of synaptic connectivity [24]—and we have demonstrated a significant proportion of ASD-implicated genes appear to be glial-specific—it is possible that genomic aberrations ultimately funnel through core signaling pathways of glial cells to disrupt formation of neural networks independent of an inflammatory mechanism. In support of this notion, a number of recent reports have demonstrated that these same cytokine signaling pathways are central to proper brain development [59,60]. Furthermore, signaling through the NFκB pathway has been shown to be important in synaptic plasticity independent of an inflammatory mechanism [61].

Moreover, two of three genome-wide expression studies in Autism brain tissue conclude that the most prominent transcriptome changes are related to neuro-immune disturbances. In the Garbett et al study, the most significant functional pathway implicated was NFκB signaling [31]. The most comprehensive transcriptomics study of ASD post-mortem brain to date (Voineagu et al) concludes that one of two significant co-expression networks is involved in immune function [32]. While our results are only a first step in linking common molecular interaction pathways to the underlying genetic heterogeneity of ASD, they
provide integrated genomic evidence, which is supported by these transcriptomics, cell, and tissue level studies that further investigation into cytokine signaling in ASD is needed.

In summary, we report the spatial and temporal expression profile of genes implicated in Autism Spectrum Disorders, in addition to the genetically and phenotypically related neurodevel-

Table 8. Cell-type specific protein expression of highly expressed ASD genes from the Human Protein Atlas database.

| Gene   | Neurons | Glia | Cerebellum |
|--------|---------|------|------------|
|        | Cortex  | Hipp | Lat Vent  | Cortex | Hipp | Lat Vent | Purkinje | Granular | Molecular |
| FABP7  | --      | --   | --        | ++     | +++  | --       | --       | --       | ++        |
| GNAS   | --      | --   | --        | --     | --   | --       | --       | --       | --        |
| GPX1   | +       | +    | --        | ++     | ++   | --       | --       | --       | --        |
| HNRPFH2| +++     | +++  | ++        | ++     | ++   | --       | --       | --       | +++       |
| HRAS   | +++     | +++  | ++        | +++    | +++  | --       | --       | --       | +++       |
| PDZD4  | ++      | ++   | ++        | ++     | +++  | ++       | --       | --       | +++       |
| RPL10  | +++     | +++  | ++        | +++    | ++   | +++      | ++       | --       | +++       |
| TSPAN7 | +++     | ++   | ++        | --     | --   | --       | --       | --       | --        |
| MAP2   | +++     | +++  | ++        | --     | --   | --       | --       | --       | +++       |
| PRKCB  | ++      | ++   | --        | --     | +    | ++       | +++      | ++       | ++        |
| MEF2C  | +++     | +++  | ++        | +++    | +++  | --       | --       | --       | +++       |
| RAPGEF4| +++     | ++   | --        | ++     | ++   | +++      | --       | --       | +++       |
| APC    | +       | +    | ++        | ++     | ++   | ++       | --       | --       | +++       |
| DCX    | +++     | +    | +         | ++     | ++   | ++       | --       | --       | +++       |
| RIMS3  | +       | +    | +         | --     | --   | +        | --       | --       | --        |
| ROBO1  | ++      | ++   | ++        | +++    | ++   | ++       | ++       | --       | ++        |
| GLO1   | ++      | ++   | ++        | ++     | ++   | --       | --       | --       | ++        |
| DLX2   | +++     | ++   | ++        | +      | +    | ++       | --       | --       | +         |
| CNR1   | ++      | +    | +         | +++    | +++  | ++       | --       | --       | +++       |
| PCDH10 | ++      | ++   | +         | +++    | +++  | --       | --       | --       | +++       |
| NLGN3  | ++      | +++  | +         | --     | --   | --       | +++      | --       | --        |
| RELN   | +       | +    | +         | --     | --   | +        | --       | --       | --        |
| CADM1  | --      | --   | --        | --     | --   | --       | ---      | ++       | --        |
| CDH22  | +       | --   | --        | --     | --   | ++       | --       | --       | ++        |

Data is reported as presented in the Atlas: +++ for “strong” expression, ++ for “moderate,” + for “weak,” and – for “negative.” These highly expressed ASD genes were not present in the database: Sest62, Gabrb3, Hsd11b1, Hla-A, Dlx1, Adora2a, Cadps2, and DHCR7. Lat vent = Lateral Ventricle, Hipp = Hippocampus. doi:10.1371/journal.pone.0024691.t008

Table 9. Correlation of AutDB genes with published transcriptome studies in ASD brain.

| Brain tissue studied | Garbet et al 2008 | Voineagu et al 2011 | Purcell et al 2001 |
|----------------------|-------------------|---------------------|-------------------|
| STC                  | 6 ASD, 6Ctrls     | 29 ASD, 29Ctrls (cortex) 11ASD, 10 Ctrl (cerebellum) | 10 ASD, 23Ctrls |
| # of samples         |                   |                     |                   |
| Transcriptome Profiling Method | U133 Plus 2.0 GeneChip(Affymetrix) | Ref8 v3 Array (Illumina) | Clontech Array and UniGEM V2 Array |
| # of genes dysregulated in ASD | 130 | 444 | 30 |
| Main findings        | ↑ Immune-related genes | Genes converge on immune and synapse modules | ↑ AMPA-type glutamate receptors |
| Dysregulated genes in AutDB | 4/130 (3%)1 | 21/444 (4.7%)2 | 1/31 (3.2%)3 |

1 SDC2, SLC9A9, DLX1, AHI1, CDH4, CDH10, DLX1, DPP6, GABRB3, HLA-A, KCNMA1, MET, NOS2A, PRKCB1, PTG52, SCN1A, SLC25A12, NLGN4Y, CADM1, A2BP1, AHI1, PCDH10, PDZD4, CADPS2, SLC9A5.
2 CNR1.
3 STC = Superior temporal cortex, PFC = Pre-frontal cortex, cere = cerebellum.
doi:10.1371/journal.pone.0024691.t009
opmental disorders Schizophrenia and Epilepsy. We found a large proportion of implicated genes are not expressed in the developing human brain, and a significant number appear to be mainly expressed in glial cells. Integrated gene-network analysis, gene ontology enrichment, and canonical pathways investigation of a subset of highly expressed ASD genes all implicate central immune signaling pathways as common to the heterogeneous interactome of the implicated genes. This work serves as a framework to link the genetic findings in ASD with transcriptome, cell, and tissue level evidence for altered immune functions in ASD patients.

**Methods**

**Neurodevelopmental Disorder Databases**

AutDB [34] and CarpeDB [62] are updated, publically downloadable databases that catalog genes implicated/associated with Autism and Epilepsy, respectively (Table S1). SZGene [63] is a similar searchable database, and we obtained datafiles directly from the curators (Table S1). In all three databases, some implicated regions are provisional loci, non-coding RNAs, pseudogenes, or otherwise not included in the NIMH Transcriptional Atlas of Human Brain Development and, therefore, were not considered. All genes used in this study and how they were implicated (e.g. GWAS, functional, etc), with corresponding references, are documented in Table S1.

**NIMH Transcriptional Atlas of Human Brain Development**

The NIMH Transcriptional Atlas of Human Brain Development (www.developinghumanbrain.org) was accessed on 2/16/2011, and the raw Gene Matrix. csv datatfile was downloaded. We re-organized the data so that rows are genes and columns are developmental time points subdivided according to brain region. While the Atlas contains data for 16 different brain regions, we narrowed our focus to those 11 that were most relevant to autism [20,41]: Dorsolateral Prefrontal Cortex (DLPFC), Ventrolateral Prefrontal Cortex (VLPFC), Medial Prefrontal Cortex (MPC), Orbital Prefrontal Cortex (OPC), Posterior Superior Temporal Cortex (PSTC), Inferior Lateral Temporal Cortex (ILTC), Hippocampus (Hipp), Amygdala (Amyg), Striatum (Stri), Cerebellum (Cere), and Primary Motor Cortex (PMC). Genes in AutDB, CarpeDB, and SZGene were parsed from the full database to create disease-specific expression databases (Tables S2, S3, S4). Our analysis only considered time points up to 23 years old.

**Gene Expression Analysis**

Expression values were divided into quintiles and given corresponding colors for heat map creation (<20 RPKM, 20–40 RPKM, 40–60 RPKM, 60–80 RPKM, >100 RPKM). Genes were then assigned to one of five tiers within each brain region based on their highest level of expression across all time points, in a conservative attempt to analyze the expression data qualitatively. For example, if a gene is expressed at 150 RPKM at 24 weeks gestation (wg) and at 80 RPKM for all other time points, it is placed in the >100 RPKM tier. Based on results from established housekeeping genes (see Results), we considered a gene to be differentially expressed if it crossed more than three tiers. Because of this, genes in the top three tiers were considered to be “highly expressed,” and were the focus of our subsequent analysis (Tables S2, S3, S4, “Highly Expressed Genes” tab).

**Gene Ontology Enrichment Analysis**

To test if a subset of genes implicated different Gene Ontology categories than a background set of all genes, we employed the Gene Ontology Enrichment Analysis and Visualization tool [64], accessed at http://cbl-gorilla.cs.technion.ac.il/. We specified the organism as *Homo sapiens*, chose the option for two unranked lists of genes, and set the p-value threshold to 0.01.

**Ingenuity Pathway Analysis**

Integrated gene-network analysis for the AutDB, CarpeDB, and SZGene sets and on the highly expressed subsets were generated by Ingenuity Pathways Analysis (Version 8.8, Ingenuity® Systems, www.ingenuity.com). Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. The gene lists were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. These focus gene networks were then algorithmically generated based on their connectivity.

Canonical pathways analysis identified the pathways from the Ingenuity Pathways Analysis library of canonical pathways that were most significant to the data set. The significance of the association between the data set and the canonical pathway was measured in two ways: i) A ratio of the number of molecules from the data set that map to the pathway divided by the total number of molecules that map to the canonical pathway and ii) Fisher’s exact test was used to calculate a p-value determining the probability that the association between the genes in the dataset and the canonical pathway is explained by chance alone. A p-value of less than 0.01 was considered significant. For comparison analysis between all disease genes and highly expressed genes, Benjamini-Hochberg multiple testing correction was used to calculate p-values, with 0.01 set as a significance threshold.

Functional Network Analysis identified the biological interactions that were most significant to the molecules in the network. The network molecules associated with biological functions and/or diseases in Ingenuity’s Knowledge Base were considered for the analysis. Right-tailed Fisher’s exact test was used to calculate a p-value determining the probability that each biological function assigned to that network is due to chance alone, with a threshold of 0.01 set for significance. A graphical representation of the molecular relationships between molecules was generated. Molecules are represented as nodes, and the biological relationship between two nodes is represented as an edge (line). All edges are supported by at least one reference from the literature. Nodes are displayed using various shapes that represent the functional class of the gene product. Edges are displayed as either solid or broken lines to describe the nature of the relationship between the nodes (solid for direct interaction, broken for an indirect interaction).

**Human Protein Atlas**

To compare expression data at the transcriptome level to protein-level expression, we accessed the Human Protein Atlas [33] at http://www.proteinatlas.org/. The Human Protein Atlas is a publicly available database cataloging the distribution of proteins in different normal human tissues, cancer types, and cell lines via validated antibody analysis. The data includes immunohistochemistry, Western blot analysis and, for a large fraction, a protein array assay and immunofluorescent based confocal microscopy. We utilized the reported levels of antibody staining as given, except for genes that contained annotated expression results, which we reported instead.

**Supporting Information**

- Figure S1 Expression profile of the 15 most constantly expressed genes identified by Hsiao *et al.* (XLS)
- Figure S2 Expression profile of 10 canonical housekeeping genes. (XLS)
Autism Candidate Genes Implicate Immune Signaling

Figure S3  Expression profiles of 5 tissue-specific Intermediate Filament Genes. NEFL is specific to neurons (Neurofilament, Entrez ID 4747), GFAP is specific to Glia (Glia Fibriallary Acidic Protein, Entrez ID 2670), VIM is specific to mesoderm derivatives (Vimentin, Entrez ID 7431), DES is specific to muscle (Desmin, Entrez ID 1674), and KRT1 (Keratin, Entrez ID 3848) is specific to epithelium.

Figure S4  Expression profile of Cannabinoid Receptor 1 and 2.

Figure S5  Expression profile of the most highly expressed ASD-implicated genes.

Figure S6  Schematic diagram of the canonical pathway “Reelin Signaling in Neurons.” Genes implicated in ASD, Epilepsy, and Schizophrenia are indicated with shading. Grey shading indicates the gene is implicated in more than one of these disorders, yellow is specific to Schizophrenia and Pink specific to ASD.

Figure S7  Overlay of ASD interactome networks by brain region for the 32 highly expressed genes. There was no significant clustering of networks by brain region. Dark blue = Amygdala, Light Blue = Motor, Turquoise = Striatum, Black = Combined frontal, Grey = Combined temporal, Beige = Hippocampus, Dark Red = Cerebellum.

Figure S8  Overlay of Schizophrenia interactome networks. Dark blue networks are from the highly expressed enriched set, light blue networks from all Schizophrenia genes analyzed. No central networks were apparent.

References

1. Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, et al. (1995) Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med 25: 63–77.
2. Steffenburg S, Gillberg C, Hellgren I, Andersson L, Gillberg IC, et al. (1989) A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry 30: 405–416.
3. Smalley SL, Azamow RF, Spence MA (1988) Autism and genetics. A decade of research. Arch Gen Psychiatry 45: 953–961.
4. Ritvo ER, Jerde LB, Mason-Brothers A, Freeman BJ, Pingree G, et al. (1989) The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. Am J Psychiatry 146: 1032–1036.
5. Abrahms BS, Geschwind DH (2008) Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet 9: 341–355.
6. Schuerer GB, Mendelsohn NJ (2008) Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med 10: 301–305.
7. Piven J, Palmer P (1997) Cognitive deficits in parents from multiple-incidence autism families. J Child Psychol Psychiatry 38: 1011–1021.
8. Ronald A, Happe F, Bolton P, Burcher LM, Price TS, et al. (2006) Genetic heterogeneity between the three components of the autism spectrum: a twin study. J Acad Child Adolesc Psychiatry 45: 691–699.
9. Mitchell KJ (2011) The genetics of neurodevelopmental disease. Curr Opin Neurobiol 21: 197–203.
10. Levy SE, Mendell DB, Schultz RT (2009) Autism. Lancet 374: 1627–1638.
11. Ching MS, Shen Y, Tao WH, Jeste SS, Morrows EM, et al. (2010) Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet B Neuropsychiatr Genet 153B: 937–947.
12.Guimaraes A, Durbouc C, Mosca AL, Legelid S, Goldenberg A, et al. (2009) Recurrent rearrangements in synaptic and neurodevelopmental genes and shared biologic pathways in schizophrenia, autism, and mental retardation. Arch Gen Psychiatry 66: 947–956.
13. Freitag CM (2007) The genetics of autistic disorders and its clinical relevance: a review of the literature. Mol Psychiatry 12: 2–22.
14. Amey R, Kri L, Pinto D, Regan R, Conroy J, et al. (2010) A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet 19: 4072–4082.
15. Holt R, Barnby G, Maestrini E, Baccelli E, Brocklebank D, et al. (2010) Linkage and candidate gene studies of autism spectrum disorders in European populations. Eur J Hum Genet 18: 1015–1019.
16. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, et al. (2007) Strong association of de novo copy number mutations with autism. Science 316: 445–449.
17. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82: 465–476.
18. Geschwind DH, Levit P (2007) Autism spectrum disorders: developmental disconnection syndromes. Curr Opin Neurobiol 17: 103–111.
19. Zoghbi HY (2003) Postnatal neurodevelopmental disorders: meeting at the cross roads? Science 302: 826–830.
20. Abrahams BS, Geschwind DH (2010) Connecting genes to brain in the autism spectrum disorders. Arch Neurol 67: 395–399.
21. Pickett J, London E (2005) The neuropathology of autism: a review. J Neuropathol Exp Neurol 64: 925–933.
22. Levit P (2003) Structural and functional maturation of the developing primate brain. J Pediatr 143: S35–45.
23. Vogel AC, Power JD, Petersen SE, Schlaggar BL (2010) Development of the brain’s functional network architecture. Neuropsychol Rev 20: 362–375.
24. Bolton MM, Erogul C (2009) Look who is wearing the neural wets glial control of synapse formation. Curr Opin Neurobiol 19: 491–497.
25. Geschwind DH (2008) Autism: many genes, common pathways? Cell 135: 391–395.
26. Levit P, Campbell DB (2009) The genetic and neurobiologic compass points toward common signaling dysfunctions in autism spectrum disorders. J Clin Invest 119: 747–754.
27. Chahroum M, Jung SY, Shaw C, Zhou X, Wong NT, et al. (2008) McCP2, a key contributor to neurological disease, activates and represses transcription. Science 320: 1224–1229.
28. Samaco RC, Hogart A, LaSalle JM (2005) Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MEG2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Genet 14: 483–492.
29. Lintas C, Sasco R, Persico AM (2010) Genome-wide expression studies in Autism spectrum disorder, Rett syndrome, and Down syndrome. Neurobiol Dis doi:10.1016/j.nbd.2010.11.010.
30. Purcell AE, Jon O, Zimmerman AW, Blue ME, Peverner J (2001) Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology 57: 1610–1620.

Acknowledgments

We would like to thank Mateusz Maciejewski for help writing PERL scripts.

Author Contributions

Conceived and designed the experiments: MNZ OMR. Performed the experiments: MNZ. Analyzed the data: MNZ OMR. Contributed reagents/materials/analysis tools: MNZ OMR. Wrote the paper: MNZ OMR.
31. Garbett K, Ebert PJ, Mitchell A, Lintas C, Manzi R, et al. (2008) Immune transcripome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 30: 303–311.

32. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, et al. (2011) Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 474: 380–384.

33. Jones AR, Overly CC, Sunkin SM (2009) The Allen Brain Atlas: 5 years and beyond. Nat Rev Neurosci 10: 821–829.

34. Basu SN, Kollu R, Binnerjee-Basu S (2009) AutDB: a gene reference resource for autism research. Nucleic Acids Res 37: D832–836.

35. Berglund L, Björling E, Öksvold P, Fagerberg L, Asplund A, et al. (2008) A gene-centric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7: 2019–2027.

36. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5: 621–628.

37. Hsiao LL, Dangond F, Yoshida T, Hong R, Jensen RV, et al. (2003) A compendium of gene expression in normal human tissues. Physiol Genomics 7: 97–104.

38. Eisenberg E, Levanon EY (2003) Human housekeeping genes are compact. J Neuroimmunol 172: 198–205.

39. Tebbenkamp AT, Borchelt DR (2010) Analysis of chaperone mRNA expression in the adult mouse brain by meta analysis of the Allen Brain Atlas. PLoS One 5: e13675.

40. Gilheeney F, Greter M, Leboeuf M, Xandri S, See P, et al. (2010) Fate mapping reveals that adult microglia derive from primitive macrophages. Science 330: 841–845.

41. Schumann CM, Nordahl CW (2011) Bridging the gap between MRI and postmortem research in autism. Brain Res 1380: 175–186.

42. Buxbaum JD, Silverman JM, Smith CJ, Greenberg DA, Kilifarski M, et al. (2002) Association between a GABRB3 polymorphism and autism. Mol Brain Res 97–104.

43. Schumann CM, Nordahl CW (2011) Bridging the gap between MRI and postmortem research in autism. Brain Res 1380: 175–186.

44. Peters J, Williamson CM (2008) Control of imprinting at the Gnas cluster. Adv Exp Med Biol 626: 16–26.

45. Sasaki Y, Shaw CA, Dawson BC, Dugas DV, Al-Mohaisen Z, et al. (2011) Protein interactome reveals converging molecular pathways among autism disorders. Sci Transl Med 3: 86ra49.

46. Goines P, Van de Water J (2010) The immune system’s role in the biology of autism. Curr Opin Neurol 23: 111–117.

47. Croonenberghs J, Bosmans E, Deboeuf D, Krens G, Maes M (2002) Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 120: 149–153.

48. Ashwood P, Emtrum A, Krakowiak P, Hertz-Picciotto I, Hansen RL, et al. (2008) Decreased transforming growth factor beta in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 204: 149–153.

49. Braunschweig D, Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, et al. (2008) Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 29: 226–231.

50. Enstrom AM, Lit L, Onore CE, Greigg JP, Hansen RL, et al. (2009) Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 23: 124–133.

51. Enstrom AM, Onore CE, Van de Water JA, Ashwood P (2010) Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 24: 64–71.

52. Vargha DL, Nascimbeni C, Krishnan C, Zimmerman AW, Pardo CA (2005) Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57: 67–81.

53. Morgan JT, Chana G, Pardo CA, Achim C, Semenderefi K, et al. (2010) Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 68: 368–376.

54. Kacimi R, Giffard RG, Yenari MA (2011) Endotoxin-activated microglia injure synapses by the elevated release of glutamate. J Neurosci 30: 5346–5356.

55. Enstrom AM, Lit L, Onore CE, Hertz-Picciotto I, Hansen RL, et al. (2009) Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 23: 124–133.

56. Kastner DL, Aksentijevich I, Godbach-Mansky R (2010) Autoinflammatory disease reloaded: a clinical perspective. Cell 140: 784–790.

57. Kastner DL, Aksentijevich I, Godbach-Mansky R (2010) Autoinflammatory disease reloaded: a clinical perspective. Cell 140: 784–790.

58. Braunschweig D, Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, et al. (2008) Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 29: 226–231.

59. Enstrom AM, Lit L, Onore CE, Greigg JP, Hansen RL, et al. (2009) Altered gene expression and function of peripheral blood natural killer cells in children with autism. Brain Behav Immun 23: 124–133.

60. Enstrom AM, Onore CE, Van de Water JA, Ashwood P (2010) Differential monocyte responses to TLR ligands in children with autism spectrum disorders. Brain Behav Immun 24: 64–71.

61. Derecki NC, Privman E, Kipis J (2010) Rett syndrome and other autism spectrum disorders-brain diseases of immune malfunction? Mol Psychiatry 15: 355–363.

62. Galperin MY (2005) The Molecular Biology Database Collection: 2005 update. Nucleic Acids Res 33: D5–24.

63. Allen NG, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, et al. (2008) Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SeGene database. Nat Genet 40: 827–834.

64. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z (2009) GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10: 48.